Skip to main content
. 2017 May 18;8(43):75646–75663. doi: 10.18632/oncotarget.17980

Figure 3. IOF’s algorithm for the management of non-metastatic bone disease in prostate cancer patients receiving ADT (modified from ref. 16).

Figure 3